Despite the availability of multiple nonheparin anticoagulants for the treatment of heparin-
induced thrombocytopenia (HIT), few data are available comparing the cost-effectiveness of …

Current guidelines for heparin-induced thrombocytopenia (HIT) management recommend
heparin cessation and switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) …

Fondaparinux is a synthetic antithrombin-binding" penta-saccharide" anticoagulant with
proven antithrombotic efficacy in a variety of prophylactic and therapeutic settings (1) …

Background The effectiveness and safety of non‐heparin anticoagulants for the treatment of
heparin‐induced thrombocytopenia (HIT) are not fully established, and the optimal treatment …

Objective: Heparin-induced thrombocytopenia (HIT) occurs in up to 5% of patients exposed
to unfractionated heparin for 5 or more days. Direct thrombin inhibitors (DTIs) are currently …

Introduction In life-threatening immune heparin-induced thrombocytopenia (HIT), treatment
with an approved non-heparin anticoagulant is essential. However, off-label use with …

First-line therapies for HIT are argatroban or lepirudin. Patient-specific factors determine
which drug should be used, and taking advantage of their differences allows effective …

Background: Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the
alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid. Frequently, the …

Background: Argatroban is the only commercially available Food and Drug Administration
(FDA)–approved anticoagulant for managing heparin-induced thrombocytopenia (HIT) …

Heparin-induced thrombocytopenia (HIT) is a drug-mediated, prothrombotic disorder caused
by immunization against platelet factor 4 (PF4) after complex formation with heparin or other …